Francesco Maria Lavino is the Chief Executive Officer of F2G. He brings more than 20 years of pharmaceutical and biotechnology experience in strategic and operational roles in the United States, Europe, and emerging markets. Prior to joining F2G, Francesco served as Chief Commercial Officer of Nabriva Therapeutics, where he led the commercial organization buildout and the launch of Xenleta®, a first-in-class antibiotic treatment. Prior to Nabriva, he spent almost 15 years at Merck and Cubist Pharmaceuticals in different commercial roles and therapeutic areas at global, regional, and country levels. Francesco held the position of Global Brand Leader for the Anti-Infective Portfolio (2015-2017) and was previously the commercial lead of the Merck Antifungal Portfolio in EMEAC (2009-2010) and globally (2011-2013). Francesco began his career in pharmaceutical sales in Italy and holds a BS in pharmacy from Federico II University of Naples, Italy, and an MBA from SDA Bocconi School of Management in Milan, Italy.